FDA warns Lepu Medical Technology Beijing that its unapproved COVID-19 test kits are adulterated and misbranded.
What happened
FDA reviewed Lepu Medical Technology (Beijing) Co., Ltd.'s offers for sale in the United States of Neutralization Antibody Test kits, a SARS-CoV-2 Antigen Rapid Test Kit, and a Saliva Antigen Rapid Test. FDA found the COVID-19 Test Kits were offered without marketing approval, clearance, or authorization and without the required 510(k) notification. The letter does not state an inspection; FDA based its findings on the product offerings.
What FDA found
The firm offered COVID-19 test kits for sale in the United States without FDA marketing approval, clearance, or authorization.
Section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B)The firm did not have an approved premarket approval (PMA) application or an approved investigational device exemption (IDE).
Sections 515(a) and 520(g) of the Act, 21 U.S.C. §§ 360e(a), 360j(g)The firm did not notify FDA of its intent to introduce the devices into commercial distribution as required by 510(k).
Section 502(o) of the Act, 21 U.S.C. § 352(o); Section 510(k), 21 U.S.C. § 360(k)The firm introduced or delivered for introduction the products into interstate commerce, which is prohibited.
Section 301(a) of the Act, 21 U.S.C. § 331(a)The firm did acts with respect to the devices while held for sale after shipment in interstate commerce that resulted in misbranding.
Section 301(k) of the Act, 21 U.S.C. § 331(k)
What FDA wants
FDA tells the firm to take immediate action to stop selling the unapproved, uncleared, and unauthorized COVID-19 test kits. Within 48 hours, the firm must email FDA with the specific steps taken, how it will prevent recurrence, and supporting documents; if it cannot act completely within 48 hours, it must state why and give a timeframe.
Who should pay attention
- US buyers and distributors of COVID-19 test kits
- labs and healthcare providers considering imported antigen or antibody tests
- brands sourcing diagnostic tests from Chinese manufacturers
This is a summary. Read the original letter on fda.gov.